ZA200510106B - Stable freeze-dried pharmaceutical formulation of tetrodotoxin - Google Patents

Stable freeze-dried pharmaceutical formulation of tetrodotoxin

Info

Publication number
ZA200510106B
ZA200510106B ZA200510106A ZA200510106A ZA200510106B ZA 200510106 B ZA200510106 B ZA 200510106B ZA 200510106 A ZA200510106 A ZA 200510106A ZA 200510106 A ZA200510106 A ZA 200510106A ZA 200510106 B ZA200510106 B ZA 200510106B
Authority
ZA
South Africa
Prior art keywords
tetrodotoxin
pharmaceutical formulation
dried pharmaceutical
stable freeze
freeze
Prior art date
Application number
ZA200510106A
Other languages
English (en)
Inventor
Zhang Xiao
Huang Xiaoyan
Kang Yuhong
Original Assignee
Nanning Maple Leaf Pharmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanning Maple Leaf Pharmaceuti filed Critical Nanning Maple Leaf Pharmaceuti
Publication of ZA200510106B publication Critical patent/ZA200510106B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
ZA200510106A 2003-07-14 2005-12-12 Stable freeze-dried pharmaceutical formulation of tetrodotoxin ZA200510106B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA031460208A CN1568999A (zh) 2003-07-14 2003-07-14 稳定的医药用河豚毒素冷冻干燥制剂

Publications (1)

Publication Number Publication Date
ZA200510106B true ZA200510106B (en) 2009-09-30

Family

ID=33752652

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200510106A ZA200510106B (en) 2003-07-14 2005-12-12 Stable freeze-dried pharmaceutical formulation of tetrodotoxin

Country Status (10)

Country Link
US (3) US8124608B2 (xx)
EP (1) EP1645277A4 (xx)
JP (1) JP2007507422A (xx)
KR (1) KR20060096411A (xx)
CN (2) CN1568999A (xx)
BR (1) BRPI0412002A (xx)
CA (1) CA2529598C (xx)
MX (1) MXPA06000243A (xx)
WO (1) WO2005004874A1 (xx)
ZA (1) ZA200510106B (xx)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
CN101039675A (zh) * 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
GT200600112A (es) 2005-03-14 2006-11-29 Composiciiones de tigeciclina y metodos de preparacion
WO2007025213A2 (en) * 2005-08-25 2007-03-01 Wex Pharmaceuticals, Inc. Use of sodium channel blockers for the management of musculoskeletal pain
EP1928452A4 (en) * 2005-08-25 2010-09-01 Wex Medical Ltd USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
CN103271920A (zh) * 2006-03-27 2013-09-04 威克斯医药有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途
CN101239061B (zh) * 2006-10-18 2011-05-11 江苏宏锦天药业有限公司 氨基全氢化喹唑啉类化合物清除生物体内瘦肉精的用途
WO2008088174A1 (en) * 2007-01-19 2008-07-24 Sang Gil Lee The composition comprising swellfish extracts using protease, and a manufacturing method thereof
CN101450056B (zh) * 2007-12-06 2013-04-24 江苏宏锦天药业有限公司 钠离子通道阻断剂用于治疗抗生素对生物耐药性的新用途
CN101554368B (zh) * 2008-04-07 2013-06-12 江苏宏锦天药业有限公司 一种室温稳定的注射用替曲朵辛组合物制剂
CN101352422B (zh) * 2008-09-17 2011-04-20 厦门朝阳生物工程有限公司 河豚毒素冻干粉针制剂及其制备方法
CN102020653A (zh) * 2009-09-22 2011-04-20 江苏宏锦天药业有限公司 氨基全氢化喹唑啉类化合物及其衍生物制备提高抗癌药药效的新应用
IN2013MU01127A (xx) 2013-03-26 2015-05-01 Astron Res Ltd
KR101398764B1 (ko) 2013-08-29 2014-05-27 강릉원주대학교산학협력단 입자의 이동에 의해 분석물질을 검출하는 장치 및 방법
CN111122752B (zh) * 2020-02-26 2022-06-10 浙江清华长三角研究院 一种河豚毒素成分分析标准物质的制备方法
CN112704665A (zh) * 2021-01-08 2021-04-27 江苏宏锦天药业有限公司 替曲朵辛口服制剂、替曲朵辛冻干片及其应用
CN115475151A (zh) * 2022-08-14 2022-12-16 中国人民解放军海军军医大学 河豚毒素缓释微球及其制备方法和用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2912361A (en) * 1956-11-28 1959-11-10 Sterling Drug Inc Canine distemper vaccine and its preparation
JPS5967228A (ja) * 1982-10-07 1984-04-16 Green Cross Corp:The 寒冷不溶性グロブリンの凍結乾燥方法
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
WO1993000807A1 (en) * 1991-07-03 1993-01-21 Cryolife, Inc. Method for stabilization of biomaterials
WO1995024903A1 (fr) * 1994-03-17 1995-09-21 Nanning Maple Leaf Pharmaceutical Co., Ltd. Application de composes de quinazoline amino-hydrogenes et de leurs derives au sevrage des toxicomanes
EP0857484A4 (en) * 1995-09-13 2000-12-06 Nippon Shinyaku Co Ltd PGE1- FREEZING DRIED PREPARATION AND METHOD FOR THE PRODUCTION THEREOF
JP2937135B2 (ja) * 1995-09-13 1999-08-23 日本新薬株式会社 Ｐｇｅ１含有凍結乾燥製剤及び製法
CN1072486C (zh) * 1996-09-24 2001-10-10 王维国 用于戒毒、镇痛的药剂及其制法
US6030975A (en) * 1997-03-14 2000-02-29 Basf Aktiengesellschaft Carboxylic acid derivatives, their preparation and use in treating cancer
US6030974A (en) * 1997-04-02 2000-02-29 The Regents Of The University Of California Method of anesthesia
US6326020B1 (en) 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
EP1058547B1 (en) * 1998-03-03 2005-11-23 Shionogi & Co., Ltd. Pharmaceutical compositions containing the phospholipase inhibitor sodium 3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl]oxy]acetate
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
CN1203857C (zh) * 2000-09-18 2005-06-01 威克斯医药有限公司 局部麻醉与镇痛的新方法
CN1240702C (zh) * 2000-09-18 2006-02-08 威克斯医药有限公司 高获得率提取替曲朵辛的方法
CN1284536C (zh) * 2000-09-18 2006-11-15 威克斯医药有限公司 河豚毒素或蛤蚌毒素及其类似物在制备用于全身镇痛的镇痛药中的应用
CN1187356C (zh) * 2000-11-22 2005-02-02 南宁枫叶药业有限公司 高获得率提取替曲朵辛的系统
CN1187355C (zh) * 2000-11-22 2005-02-02 南宁枫叶药业有限公司 精制高纯度替曲朵辛的方法
CN1236773C (zh) * 2000-11-22 2006-01-18 南宁枫叶药业有限公司 用于镇痛、麻醉或治疗药物依赖性的制剂
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN1203860C (zh) * 2001-06-22 2005-06-01 威克斯医药有限公司 钠离子通道阻断剂和阿司匹林在制备用于对哺乳动物进行协同镇痛的药物中的应用
CN100360133C (zh) 2002-05-23 2008-01-09 潘心富 用于戒毒、镇痛的河豚毒素呼吸道给药制剂
CN1158285C (zh) * 2002-06-24 2004-07-21 厦门一元生物工程有限公司 河豚毒素高纯单体规模化制备方法
CN1568999A (zh) * 2003-07-14 2005-01-26 南宁枫叶药业有限公司 稳定的医药用河豚毒素冷冻干燥制剂
US20050197303A1 (en) 2003-10-31 2005-09-08 Bausch & Lomb Incorporated Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
US20090143415A1 (en) 2004-09-21 2009-06-04 Wex Pharmaceuticals, Inc. Tetrodotoxin And Its Derivatives For The Treatment Of Central-Nervously Derived Neuropathic Pain
CN101039675A (zh) 2004-09-22 2007-09-19 埃斯蒂文博士实验室股份有限公司 河豚毒素及其衍生物用于治疗外周神经源性神经痛
EP1928452A4 (en) 2005-08-25 2010-09-01 Wex Medical Ltd USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
CN103271920A (zh) 2006-03-27 2013-09-04 威克斯医药有限公司 钠通道阻滞剂治疗由于化疗而产生的神经病理性疼痛的用途

Also Published As

Publication number Publication date
KR20060096411A (ko) 2006-09-11
CN1835754A (zh) 2006-09-20
US20050020610A1 (en) 2005-01-27
JP2007507422A (ja) 2007-03-29
CN100457110C (zh) 2009-02-04
US20100249150A1 (en) 2010-09-30
WO2005004874A1 (fr) 2005-01-20
US8530481B2 (en) 2013-09-10
US8124608B2 (en) 2012-02-28
BRPI0412002A (pt) 2006-08-15
CA2529598C (en) 2017-03-07
CA2529598A1 (en) 2005-01-20
CN1568999A (zh) 2005-01-26
US20120264767A1 (en) 2012-10-18
MXPA06000243A (es) 2006-04-07
EP1645277A4 (en) 2011-08-17
US8222258B2 (en) 2012-07-17
EP1645277A1 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
ZA200510106B (en) Stable freeze-dried pharmaceutical formulation of tetrodotoxin
EP1660043A4 (en) FORMULATION WITH IMMEDIATE RELEASE OF ACID ELASTIC PHARMACEUTICAL COMPOSITIONS
ZA200602213B (en) Pharmaceutical formulation comprising lanthanum compounds
GB0323908D0 (en) Pharmaceutical foam formulation
GB0302671D0 (en) Pharmaceutical formulations
EP1631239A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE COMPOUNDS OF VITAMIN D
HK1089094A1 (en) Pharmaceutical formulation comprising levothyroxine sodium
TWI319318B (en) Modified release pharmaceutical formulation
EP1646355A4 (en) PHARMACEUTICAL FORMULATIONS
PL1655026T3 (pl) Zawierające diacereinę i meloksikam stałe preparaty farmaceutyczne
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
AU2002364468A1 (en) Solid orally-dispersible pharmaceutical formulation
GB0202900D0 (en) Novel formulations of drugs
IL149377A0 (en) Pharmaceutical formulation comprising melatonin
AU2003257982A1 (en) Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
IL172096A0 (en) Pharmaceutical formulations comprising amoxicillin and clavulanate
AU2003280387A1 (en) Pharmaceutical formulation comprising azithrocycin monohydrate
IL172304A0 (en) Pharmaceutical compositions comprising active vitamin d compounds
GB0201607D0 (en) Formulation for the administration of medicinal substances
GB0310881D0 (en) Pharmaceutical formulation
AU2003238900A8 (en) Pharmaceutical formulation
GB0317345D0 (en) Formulation for the administration of medicinal substances
GB0302435D0 (en) Pharmaceutical formulation
AU2003904627A0 (en) Pharmaceutical Formulation
GB0225041D0 (en) Pharmaceutical formulation